Vident Investment Advisory’s Rubius Therapeutics, Inc RUBY Stock Holding History

Vident Investment Advisory’s Portfolio RUBY Stock Details RUBY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-90,978	Closed	-$501K	–	1392
2022 Q1	$501K	Buy	90,978 +15,165	+20%	+$96.3K	0.01%	926
2021 Q4	$734K	Buy	75,813 +20,479	+37%	+$284K	0.02%	817
2021 Q3	$989K	Sell	55,334 -3,952	-7%	-$86K	0.03%	680
2021 Q2	$1.45M	Buy	+59,286	New	+$1.48M	0.04%	536

Other funds holding RUBY

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AFM

Abbot Financial Management Andover, Massachusetts $239M AUM 27.19% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vident Investment Advisory's RUBY Position: Q2 2022 in Review

Vident Investment Advisory sold out of Rubius Therapeutics, Inc (RUBY) in Q2 2022, closing a stake of 90,978 shares — an estimated $501K sold.

Vident Investment Advisory first reported a position in RUBY in Q2 2021 and held it in 4 quarters. The position peaked at $1.45M in Q2 2021. 72 funds tracked by Wall St. Rank hold RUBY as of Q2 2022.

Vident Investment Advisory reported no remaining Rubius Therapeutics, Inc position as of Q2 2022 after selling out during the quarter.
Vident Investment Advisory sold 90,978 Rubius Therapeutics, Inc shares in Q2 2022, an estimated $501K.
Vident Investment Advisory first reported a position in Rubius Therapeutics, Inc in Q2 2021 and held it in 4 quarters.
Vident Investment Advisory's Rubius Therapeutics, Inc position peaked at $1.45M in Q2 2021.
72 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q2 2022.

Based on Vident Investment Advisory's 13F filing for Q2 2022, filed 15 Aug 2022.